Modulation of allogenic reaction by ticlopidine treatment.
Ability of response in proliferation and cytotoxicity of lymphocytes, after in vitro allogeneic reaction was tested in three independent series of experiments, before and after seven days of ticlopidine treatment (500 mg daily) taken by normal adult individuals. In the third experiment, blood samples were taken twice before treatment and twice during the treatment. In two of the three series of experiments the ability of proliferation of responding cells in a mixed lymphocyte reaction was decreased (P less than 0.01). Cytotoxicity was reduced in the three series of experiments when the combination effector/target cells after treatment was compared with the combination before treatment (P less than 0.01 - 0.001), at various effector to target cells ratios for one target (50:1 and 100:1).
Degos
L
L
INSERM U93, Hôpital St Louis, Centre Hayem, Paris, France.
Bourges
J F
JF
Bensussan
A
A
Zini
J M
JM
Thebault
J J
JJ
Tobelem
G
G
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000328:Adult; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008213:Lymphocyte Activation / Q000187:drug effects; D007959:Lymphocyte Culture Test, Mixed; D008214:Lymphocytes / Q000187:drug effects* / Q000276:immunology; D008297:Male; D008875:Middle Aged; D013988:Ticlopidine / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D013988:Ticlopidine